A Study to Evaluate the Efficacy of PanCytoVir™ for the Treatment of Non-Hospitalized Patients With COVID-19 Infection
COMPLETED: This was a randomized, single-center, single-blind, placebo controlled, study to evaluate efficacy of PanCytoVir™ 500 mg twice daily and 1000 mg twice daily for the treatment of non-hospitalized patients with COVID-19 infection.
Estimated Enrollment: 75 participants
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment